ANI Pharmaceuticals Inc (ANIP) 30.60 $ANIP
Illumina Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 1:10PM CDT
On May 10, we upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:05AM CDT
RadNet (RDNT) recorded an earnings surprise in 3 of its last 4 quarters, with an average beat of 133.96%.
RadNet (RDNT) Surges: Stock Moves 21.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:21AM CDT
RadNet, Inc. (RDNT) was a big mover last session, as the company saw its shares rise by almost 22% on the day.
XOMA Posts Wider Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 3:00PM CDT
XOMA Corporation (XOMA) posts wider-expected loss in the first quarter of 2014.
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Why ANI Pharmaceuticals Inc. Shares Briefly Slipped
Sean Williams, The Motley Fool - Motley Fool - Mon May 05, 12:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ANI Pharmaceuticals , a developer of...
ANI Pharmaceuticals Reports Record Net Revenues of $10.9 million, EPS of $0.33, and Adjusted Non-GAAP EBITDA of $4.2 Million for the First Quarter Ended March 31, 2014
PR Newswire - Mon May 05, 7:30AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today reported financial results for the three months ended March 31, 2014.
Transdermal Drug Delivery Market & Clinical Pipeline Insight Report 2014 - Detailed Analysis of the $25 Billion Industry
M2 - Fri May 02, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdr2kp/transdermal_drug) has announced the addition of the "Transdermal Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation. Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations. Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance. There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe. Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life. Key Topics Covered: 1. Introduction to Transdermal Drug Delivery 2. Transdermal Drug Delivery Mechanism 3. Why Need For Transdermal Drug Delivery? 4. Transdermal Drug Delivery Market Outlook 5. Transdermal Drug Delivery Market Dynamics 6. Future of Transdermal Drug Delivery Market 7. Guidelines/Regulations for Transdermal Drug Delivery 8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications 9. Marketed Transdermal Drug Profiles 10. Suspended & Discontinued Transdermal Drug Profiles 11. Competitive Landscape - Acrux, - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Dermatrends Inc - Durect Corporation - Nuvo Research - Novartis - Phosphagenics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/bd...ermal_drug
ANI Pharmaceuticals Expands Product Development Collaboration with Sofgen
PR Newswire - Thu May 01, 8:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI" (Nasdaq: ANIP) announced today that it has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals ("Sofgen" for the development of an ANDA soft gel oral drug product. Sofgen will be responsible for development, manufacturing and regulatory submission of the drug and ANI will be responsible for marketing and distribution in the U.S. Prior to recent generic entry the product had branded annual U.S. sales of approximately $1 billion, per IMS Health. Financial terms of the agreement were not disclosed.
ANI Pharmaceuticals Schedules Conference Call for First Quarter 2014 Financial Results
PR Newswire - Mon Apr 28, 7:30AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2014 financial results on Monday, May 5, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Biotech of the Week: ANI Pharmaceuticals, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
ANI Pharmaceuticals is the biotech of the week on the Fool's weekly show Biotech Banter . Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went...
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 27, 10:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.
Allergan Inc. (AGN) in Focus: Stock Rallies 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:44AM CDT
Allergan Inc. was a big mover last session, as the company saw its shares surge over 15.0% on the day.
ANI Pharmaceuticals, Inc. (ANIP) Looks Strong: Stock Soars 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:44AM CDT
ANI Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge nearly 21% on the day.
3 Stocks Rising on Unusual Volume
at The Street - Tue Apr 22, 6:42AM CDT
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Narrower-than-Expected Loss at Cepheid, View Tweaked - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 12:04PM CDT
Cepheid (CPHD) reported a loss of 10 cents per share in the first quarter of 2014, a substantial decrease from the year-ago income of 2 cents a share.
Major Indexes Hold Small Gains In Quiet Trade
at Investor's Business Daily - Mon Apr 21, 11:04AM CDT
The major averages continued to hold modest gains in quiet late-morning trade Monday as the Nasdaq and S&P 500 were up 0.2% each and the Dow Jones industrial average climbed 0.1%. Volume was tracking lower across the board vs. Thursday in the stock...
Illumina Upgraded to Strong Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 1:10PM CDT
On May 10, we upgraded Illumina Inc. (ILMN) to a Zacks Rank #1 (Strong Buy).
RadNet Touches New 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 9:05AM CDT
RadNet (RDNT) recorded an earnings surprise in 3 of its last 4 quarters, with an average beat of 133.96%.
RadNet (RDNT) Surges: Stock Moves 21.8% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon May 12, 8:21AM CDT
RadNet, Inc. (RDNT) was a big mover last session, as the company saw its shares rise by almost 22% on the day.
XOMA Posts Wider Q1 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 3:00PM CDT
XOMA Corporation (XOMA) posts wider-expected loss in the first quarter of 2014.
Q1 Loss Wider than Expected at Genomic Health - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri May 09, 2:30PM CDT
Following the disappointing earnings performance, Genomic Health's share price declined 1.5% on May 8.
Zacks Rank #1 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
Why ANI Pharmaceuticals Inc. Shares Briefly Slipped
Sean Williams, The Motley Fool - Motley Fool - Mon May 05, 12:16PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ANI Pharmaceuticals , a developer of...
ANI Pharmaceuticals Reports Record Net Revenues of $10.9 million, EPS of $0.33, and Adjusted Non-GAAP EBITDA of $4.2 Million for the First Quarter Ended March 31, 2014
PR Newswire - Mon May 05, 7:30AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(NASDAQ: ANIP) today reported financial results for the three months ended March 31, 2014. Transdermal Drug Delivery Market & Clinical Pipeline Insight Report 2014 - Detailed Analysis of the $25 Billion Industry
M2 - Fri May 02, 8:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bdr2kp/transdermal_drug) has announced the addition of the "Transdermal Drug Delivery Market & Clinical Pipeline Insight" report to their offering. Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation. Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations. Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance. There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe. Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life. Key Topics Covered: 1. Introduction to Transdermal Drug Delivery 2. Transdermal Drug Delivery Mechanism 3. Why Need For Transdermal Drug Delivery? 4. Transdermal Drug Delivery Market Outlook 5. Transdermal Drug Delivery Market Dynamics 6. Future of Transdermal Drug Delivery Market 7. Guidelines/Regulations for Transdermal Drug Delivery 8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications 9. Marketed Transdermal Drug Profiles 10. Suspended & Discontinued Transdermal Drug Profiles 11. Competitive Landscape - Acrux, - ANI Pharmaceuticals - Antares Pharma - Bayer HealthCare Pharmaceuticals - Dermatrends Inc - Durect Corporation - Nuvo Research - Novartis - Phosphagenics - Zosano Pharma For more information visit http://www.researchandmarkets.com/research/bd...ermal_drug
ANI Pharmaceuticals Expands Product Development Collaboration with Sofgen
PR Newswire - Thu May 01, 8:00AM CDT
ANI Pharmaceuticals, Inc. ("ANI"
(Nasdaq: ANIP) announced today that it has signed an exclusive licensing, development and supply agreement with Sofgen Pharmaceuticals ("Sofgen" for the development of an ANDA soft gel oral drug product. Sofgen will be responsible for development, manufacturing and regulatory submission of the drug and ANI will be responsible for marketing and distribution in the U.S. Prior to recent generic entry the product had branded annual U.S. sales of approximately $1 billion, per IMS Health. Financial terms of the agreement were not disclosed. ANI Pharmaceuticals Schedules Conference Call for First Quarter 2014 Financial Results
PR Newswire - Mon Apr 28, 7:30AM CDT
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its first quarter 2014 financial results on Monday, May 5, 2014, before the opening of the U.S. financial markets. The earnings press release will be accessible through the Investor Relations section of the Company's website, www.anipharmaceuticals.com.
Biotech of the Week: ANI Pharmaceuticals, Inc.
Brian Orelli, The Motley Fool - Motley Fool - Sun Apr 27, 1:00PM CDT
ANI Pharmaceuticals is the biotech of the week on the Fool's weekly show Biotech Banter . Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went...
5 of Last Week's Biggest Winners
Rick Munarriz, The Motley Fool - Motley Fool - Sun Apr 27, 10:00AM CDT
It was a rocky week on Wall Street, with Nasdaq stocks inching lower and the Dow inching higher, but there were plenty of stocks really making some serious moves. Let's take a closer look at five of this past week's biggest scorchers. ...
Upcoming Conference Calls, Commencement of Shipments, Stock Price Movements, Awareness Campaigns, and Acquisitions - Analyst Notes on Incyte, Impax, ANI, Ironwood and Aastrom
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Incyte Corporation (NASDAQ: INCY), Impax Laboratories Inc. (NASDAQ: IPXL), ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Aastrom Biosciences, Inc. (NASDAQ: ASTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1519-100free.
Allergan Inc. (AGN) in Focus: Stock Rallies 15.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 7:44AM CDT
Allergan Inc. was a big mover last session, as the company saw its shares surge over 15.0% on the day.
ANI Pharmaceuticals, Inc. (ANIP) Looks Strong: Stock Soars 20.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 7:44AM CDT
ANI Pharmaceuticals, Inc. was a big mover last session, as the company saw its shares surge nearly 21% on the day.
3 Stocks Rising on Unusual Volume
at The Street - Tue Apr 22, 6:42AM CDT
Unusual volume can signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.
Nasdaq stocks posting largest percentage increases
AP - Mon Apr 21, 12:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Narrower-than-Expected Loss at Cepheid, View Tweaked - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 12:04PM CDT
Cepheid (CPHD) reported a loss of 10 cents per share in the first quarter of 2014, a substantial decrease from the year-ago income of 2 cents a share.
Major Indexes Hold Small Gains In Quiet Trade
at Investor's Business Daily - Mon Apr 21, 11:04AM CDT
The major averages continued to hold modest gains in quiet late-morning trade Monday as the Nasdaq and S&P 500 were up 0.2% each and the Dow Jones industrial average climbed 0.1%. Volume was tracking lower across the board vs. Thursday in the stock...
